peptide cdmo news makes silica-based peptides - Polypeptide Investor Relations Peptide and Oligonucleotide CDMO Market was valued at USD 2.3 billion in 2023 Peptide CDMO News: A Booming Sector Driven by Innovation and Market Growth

Polypeptide Investor Relations The peptide CDMO news landscape is buzzing with activity, reflecting a sector experiencing significant expansion and strategic investment. As the demand for peptide-based therapeutics and active pharmaceutical ingredients (APIs) continues to surge, Contract Development and Manufacturing Organizations (CDMOs) specializing in peptide synthesis and manufacturing are at the forefront of innovationEurofins CDMO Alphora Joins International Consortium .... This dynamic market is characterized by substantial growth projections, strategic acquisitions, and significant investments in expanding capabilities, particularly in areas like GLP-1 peptide synthesis.peptide-focused CRDMO

The global peptide and oligonucleotide CDMO market size is a key indicator of this growth. Recent reports indicate that the market was valued at USD 2.80 billion in 2024 and is projected to reach USD 8.14 billion by 2033, demonstrating a robust compound annual growth rate (CAGR). Another analysis shows the Peptide and Oligonucleotide CDMO Market was valued at USD 2.3 billion in 2023 and is expected to register a CAGR of over 12.1% from 2024 to 20322025年3月5日—CDMO CordenPharma expands GLP-1 peptide platformwith €500m greenfield manufacturing facility construction near Basel, Switzerland in .... Further projections suggest the global Peptide CDMO market is expected to surge to USD 16.Peptide API Market Size Forecast to Surpass USD 94.2 ...74 billion by 2032.Eurofins CDMO Alphora Joins International Consortium ... The peptide and oligonucleotide CDMO market is forecast to reach USD 3.GLP-1 Peptide Synthesis CDMO Market Size, Share and ...5 billion in 2024, growing at a CAGR of 15.1% through 2034, driven by rising demand for custom solutions. The Global Peptide CDMO Services market was valued at USD 3867M in 2024 and is projected to reach USD 10800M by 2032, at an impressive CAGR of 16.2%. In a broader scope, the global CDMO market for peptides and oligonucleotides is expected to reach $5.67 billion by 2030.

This rapid expansion is fueled by several factors, including increasing biologics R&D, strategic partnerships, and continuous innovation within the peptide therapeutics CDMO market, which continues to grow. The development of novel therapeutic peptides and the increasing complexity of manufacturing processes necessitate specialized expertise, which CDMOs provide.

Key Developments and Strategic Moves in the Peptide CDMO Sector:

Several prominent players are making significant strides in the peptide CDMO space. SK pharmteco is actively investing in its capabilities, with recent news highlighting its SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility.2025年10月24日—SK pharmteco announces a .1 million investmentin its Rancho Cordova, California facility to expand lab and CGMP-kilo-scale capabilities ... This includes a $63天前—Nanologica, a life sciences company thatmakes silica-based peptidesfor the pharmaceutical industry, acquired CDMO Ardena's Syntagon ....1 million investment in its Rancho Cordova, California facility to expand lab and CGMP-kilo-scale capabilities. This strategic move underscores the company's commitment to enhancing its peptide development and manufacturing capacity2025年3月5日—CDMO CordenPharma expands GLP-1 peptide platformwith €500m greenfield manufacturing facility construction near Basel, Switzerland in ....

PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, is also a key entity in this market. The company is recognized for its specialized services, catering to a fast-growing market2天前—Eurofins CDMO Alphora Joins International Consortium Projectto Advance Next Generation ADC Expression Platform. February 5, 2026 10:30 AM.. Discussions around PolyPeptide Investor Relations suggest a strong focus on growth and strategic development.2025年11月14日—The global oligonucleotideCDMOmarket by sales revenue grew from US..5 billion in 2018 to US.3 billion in 2023, representing a CAGR of. 33.8 ...

CordenPharma is making substantial investments to expand its peptide offerings. The company announced its largest strategic investment to date with a committed spend of approximately €900 million over the next 3 years to grow its Peptide technology platform. This includes the construction of a new €500 million Switzerland Peptide manufacturing facility near Basel, which will expand its GLP-1 peptide platform.

Eurofins CDMO Alphora has been active in collaborative efforts, notably joining an International Consortium Project to Advance Next Generation ADC Expression Platform.CordenPharma Builds >€500m Switzerland Peptide ... This groundbreaking project aims to develop a novel, high-yield expression platform that integrates optimized affinity peptide tags directly, showcasing innovation in peptide applications.

Acquisitions are also shaping the market. Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. This acquisition is expected to strengthen Granules India's position in the global peptide API market2天前—This ground breaking project aims to develop a novel, high yield expression platform that integrates optimized affinitypeptidetags directly ....

Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, recently acquired Ardena's Syntagon facility, further consolidating its position.GLP-1 Peptide Synthesis CDMO Market Size, Share and ...

AmbioPharm, described as a growing and global peptide CDMO, is regularly featured in the news as a leader in the peptide manufacturing industry, highlighting its expertise and market presence.

Emerging Trends and Market Drivers:

The growth in the peptide CDMO sector is also being driven by the increasing success of specific peptide drugs. For instance, the rapid development of peptide CDMO in China is notable, with references to the significant sales of drugs like Novo Nordisk's semaglutide and Eli Lilly's Tirzepatide, which are peptide-based. This success spurs further investment and development in the peptide API market, which was valued at US$ 9CordenPharma Builds >€500m Switzerland Peptide ....2 billion in 2023 and is forecasted to surpass USD 94.Peptide and Oligonucleotide CDMO Market Size2 billion by 2034.

The market also sees collaborations aimed at enhancing efficiency and quality. For example, HLB Pep Signs MOU with YMC Korea to Strengthen High-quality peptide active pharmaceutical ingredient production.

In summary, the peptide CDMO news reflects a vibrant and rapidly evolving industry. With substantial market valuations, significant investments in infrastructure and technology, and a consistent stream of strategic partnerships and acquisitions, the future of peptide development and manufacturing appears exceptionally promising. The ongoing innovation in peptide synthesis, coupled with the increasing demand for complex therapeutic molecules, ensures that CDMOs specializing in peptide services will continue to play a pivotal role in advancing global healthcare{plog:serpgr}